Skip to main content

Publications

featured publications

  • The value of tumor markers in men with metastatic prostate cancer undergoing [ Lu]Lu-PSMA therapy.

    The Prostate

    Authors: Anna Yordanova, Paula Linden, Stefan Hauser, Georg Feldmann, Peter Brossart, Rolf Fimmers, Markus Essler, Stefan Holdenrieder, Hojjat Ahmadzadehfar

  • Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.

    Oral oncology

    Authors: Nabil F Saba, George Blumenschein, Joel Guigay, Lisa Licitra, Jerome Fayette, Kevin J Harrington, Naomi Kiyota, Maura L Gillison, Robert L Ferris, Vijayvel Jayaprakash, Li Li, Peter Brossart

  • Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

    Clinical cancer research : an official journal of the American Association for Cancer Research

    Authors: Robert L Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Kevin J Harrington, Joel Guigay, Everett E Vokes, Nabil F Saba, Robert Haddad, Shanmugasundaram Ramkumar, Jeffery Russell, Peter Brossart, Makoto Tahara, A Dimitrios Colevas, Fernando Concha-Benavente, Mark Lynch, Li Li, Maura L Gillison

  • Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    Authors: Padmanee Sharma, Arlene Siefker-Radtke, Filippo de Braud, Umberto Basso, Emiliano Calvo, Petri Bono, Michael A Morse, Paolo A Ascierto, Jose Lopez-Martin, Peter Brossart, Kristoffer Rohrberg, Begoña Mellado, Bruce S Fischer, Stephanie Meadows-Shropshire, Abdel Saci, Margaret K Callahan, Jonathan Rosenberg

  • Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy.

    Frontiers in oncology

    Authors: Katjana S Schwab, Glen Kristiansen, Alexander Isaak, Stefanie E A Held, Annekristin Heine, Peter Brossart

  • Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.

    Clinical nuclear medicine

    Authors: Anna Yordanova, Harriet Ahrens, Georg Feldmann, Peter Brossart, Florian C Gaertner, Christian Fottner, Matthias M Weber, Hojjat Ahmadzadehfar, Mathias Schreckenberger, Matthias Miederer, Markus Essler

  • The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.

    Bone marrow transplantation

    Authors: Tobias A W Holderried, Alessia Fraccaroli, Martin Schumacher, Annkristin Heine, Peter Brossart, Matthias Stelljes, Sebastian Klobuch, Nicolaus Kröger, Petya Apostolova, Jürgen Finke, Robert Zeiser, Thomas Heinicke, Martin Bornhäuser, Michael von Bergwelt-Baildon, Johanna Tischer, Dominik Wolf

  • EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress.

    Journal of oncology

    Authors: Savita Bisht, Jens Nolting, Jörg Wenzel, Peter Brossart, Georg Feldmann